PR Newswire·Nov 10, 2026, 8:30 AM ET

Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models

Azitra Inc. announced that Cofounder & Chief Operating Officer Travis Whitfill will present pipeline updates at the BIO-Europe conference in Cologne, Germany on November 10, 2026.
The presentation will cover ATR-COSF, a recombinant filaggrin protein designed to reduce fine lines & wrinkles, with initial results from its first-in-human study anticipated by year-end 2026.
Ex vivo human skin models showed ATR-COSF achieved a 56% reduction in wrinkles & improved elasticity in the 4% formulation.
Dr. Whitfill will also provide updates on ATR-04, an investigational live biotherapeutic for cancer treatment-associated rashes, noting its Phase 1/2 trial expansion in October 2026 to include patients on KRAS & MEK inhibitors.
The ATR-04 trial expansion adds approximately 85,000 potential patients annually in the U.S. who use KRAS or MEK inhibitors to the existing 220,000 patients treated with EGFR inhibitors.
Azitra holds Fast Track designation from the FDA for cancer treatment-associated rash, impacting up to 300,000 people in the U.S.
Dr. Whitfill will conduct one-on-one meetings with potential partners & investors during the conference, with presentation slides available at ir.azitrainc.com.